Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | PDE1A | P54750 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857346 | 0.96 | MCHR1 (0.52) | MCHR1SLC6A4CHRNA7PDE1ACYP3A4 | |
| SCHEMBL3857871 | 0.82 | SLC6A4 (0.46) | MCHR1SLC6A4PDE1ACYP3A4CYP1A2 | |
| SCHEMBL94417 | 0.81 | MCHR1 (0.51) | MCHR1CHRNA7NR1I2 | |
| SCHEMBL3859870 | 0.80 | SLC6A4 (0.57) | MCHR1SLC6A4PDE1ACYP3A4CYP1A2 | |
| Mimbane SCHEMBL488924 | 0.79 | SLC6A4 (0.48) | MCHR1SLC6A4CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL19161100 | 0.79 | MCHR1 (0.41) | MCHR1CHRNA7PDE1ACYP3A4CYP1A2 | |
| Mimbane SCHEMBL29658183 | 0.78 | SLC6A4 (0.47) | MCHR1SLC6A4CYP1A2CYP2D6ADRA1A | |
| SCHEMBL10577890 | 0.78 | SLC6A4 (0.43) | MCHR1SLC6A4PDE1ACYP3A4CYP1A2 | |
| SCHEMBL10577899 | 0.78 | SLC6A4 (0.43) | MCHR1SLC6A4PDE1ACYP3A4CYP1A2 | |
| SCHEMBL10577896 | 0.78 | SLC6A4 (0.43) | MCHR1SLC6A4PDE1ACYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2007-12-20 | — | — | US | claimed |
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | DIN BELLE DAVID | 2006-05-04 | — | — | US | claimed |
| US-7592350-B2 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2009-09-22 | — | — | US | disclosed |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ORION CORPORATION (FI) | 2007-12-20 | — | — | US | disclosed |
| EP-1490361-B1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORP (FI) | 2007-10-03 | — | — | EP | disclosed |
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | DIN BELLE DAVID | 2006-05-04 | — | — | US | disclosed |
| US-3943148-A | Indole fused heterocyclic diuretic compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094740-A1 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | MCHR1 285/4885SLC6A4 1189/4885CHRNA7 75/4885 |
| US-20070293527-A9 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | ADRB2, ADRA2A, ADRB1 | MCHR1 285/4885SLC6A4 1189/4885CHRNA7 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.